

Robert C Doebele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/827148/publications.pdf>

Version: 2024-02-01

164
papers

23,250
citations

17440

63
h-index

8396

147
g-index

170
all docs

170
docs citations

170
times ranked

20896
citing authors

#	ARTICLE	IF	CITATIONS
1	Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib. <i>Molecular Oncology</i> , 2022, 16, 2000-2014.	4.6	10
2	GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers. <i>Communications Biology</i> , 2022, 5, 373.	4.4	7
3	Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100332.	1.1	15
4	Abstract 5233: Evolution of therapy resistance through acquired KRAS amplification in ROS1 fusion KRAS G12C double positive NSCLC. <i>Cancer Research</i> , 2022, 82, 5233-5233.	0.9	2
5	Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma. <i>JCI Insight</i> , 2022, 7, .	5.0	5
6	HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved Survival. <i>Journal of Thoracic Oncology</i> , 2021, 16, 104-112.	1.1	6
7	Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 156-161.	1.1	22
8	High dose acetaminophen inhibits STAT3 and has free radical independent anti-cancer stem cell activity. <i>Neoplasia</i> , 2021, 23, 348-359.	5.3	9
9	Activity of tarloxotinib in cells with EGFR exon20 insertion mutations and mechanisms of acquired resistance. <i>Thoracic Cancer</i> , 2021, 12, 1511-1516.	1.9	15
10	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1253-1263.	1.6	74
11	Novel Human-Derived RET Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling. <i>Molecular Pharmacology</i> , 2021, 99, 435-447.	2.3	6
12	A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer. <i>Npj Precision Oncology</i> , 2021, 5, 41.	5.4	22
13	Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 959-969.	10.7	222
14	Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study. <i>Translational Lung Cancer Research</i> , 2021, 10, 3659-3670.	2.8	7
15	Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 1271-1282.	1.4	12
16	Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. <i>Journal of Clinical Oncology</i> , 2021, 39, 2791-2802.	1.6	32
17	Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. <i>Clinical Cancer Research</i> , 2021, 27, 1463-1475.	7.0	52
18	Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC. <i>Npj Precision Oncology</i> , 2021, 5, 91.	5.4	5

#	ARTICLE	IF	CITATIONS
19	Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials. <i>Lancet Oncology</i> , The, 2020, 21, 261-270.	10.7	303
20	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. <i>Lancet Oncology</i> , The, 2020, 21, 271-282.	10.7	1,034
21	Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non–Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e191-e204.	2.6	26
22	Development of syngeneic murine cell lines for use in immunocompetent orthotopic lung cancer models. <i>Cancer Cell International</i> , 2020, 20, 417.	4.1	12
23	Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. <i>Cell</i> , 2020, 182, 1232-1251.e22.	28.9	371
24	Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 510.	2.8	3
25	Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma. <i>BMC Cancer</i> , 2020, 20, 177.	2.6	4
26	Duration of Targeted Therapy in Patients With Advanced Non–small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis. <i>Clinical Lung Cancer</i> , 2020, 21, 545-552.e1.	2.6	11
27	Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms. , 2020, 8, e000441.		28
28	Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating <i>RET</i> Alterations and Oncogenic Signaling Pathway Aberrations. <i>Clinical Cancer Research</i> , 2019, 25, 5832-5842.	7.0	64
29	Acquired Resistance Is Oncogene and Drug Agnostic. <i>Cancer Cell</i> , 2019, 36, 347-349.	16.8	26
30	Dramatic Response to Lorlatinib in a Patient With CD74-ROS1-Positive Lung Adenocarcinoma With Acquired F2004V Mutation. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	3.0	5
31	Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1558-1565.	1.6	882
32	A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 195.	2.8	48
33	ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events. <i>Journal of Thoracic Oncology</i> , 2019, 14, 596-605.	1.1	56
34	Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non–Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 691-700.	1.1	108
35	Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, 1095-1102.	3.7	37
36	HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. <i>Annals of Oncology</i> , 2019, 30, 447-455.	1.2	151

#	ARTICLE	IF	CITATIONS
37	A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. <i>Cancer Discovery</i> , 2019, 9, 384-395.	9.4	88
38	Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. <i>Annals of Oncology</i> , 2019, 30, 325-331.	1.2	110
39	Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins. <i>Cancer Research</i> , 2019, 79, 546-556.	0.9	59
40	Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 341-355.	27.6	347
41	Targeted therapies for ROS1-rearranged non-small cell lung cancer. <i>Drugs of Today</i> , 2019, 55, 641.	1.1	16
42	Efficacy of Larotrectinib in <i>TRK</i> Fusion-Positive Cancers in Adults and Children. <i>New England Journal of Medicine</i> , 2018, 378, 731-739.	27.0	2,036
43	Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. <i>Nature Medicine</i> , 2018, 24, 638-646.	30.7	351
44	Resistance Mechanisms to Targeted Therapies in <i>ROS1</i> + and <i>ALK</i> + Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3334-3347.	7.0	182
45	Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in <i>ALK</i> and EGFR Driven Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 715-720.	1.1	48
46	Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 364, 494-503.	2.5	85
47	The importance of the initial response to cancer treatment in predicting longer overall survival. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 109-111.	3.1	0
48	Larotrectinib Is Highly Active in Patients With Advanced Recurrent <i>TRK</i> Fusion Thyroid (TC) and Salivary Gland Cancers (SGC). <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1318.	0.8	6
49	Clinical Utility of Cell-Free DNA for the Detection of <i>ALK</i> Fusions and Genomic Mechanisms of <i>ALK</i> Inhibitor Resistance in Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2758-2770.	7.0	143
50	<i>ALK</i> Inhibitor Response in Melanomas Expressing <i>EML4-ALK</i> Fusions and Alternate <i>ALK</i> Isoforms. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 222-231.	4.1	38
51	Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2018, 13, 134-138.	1.1	21
52	Clinicopathologic Features of Non-small-Cell Lung Cancer Harboring an <i>NTRK</i> Gene Fusion. <i>JCO Precision Oncology</i> , 2018, 2018, 1-12.	3.0	112
53	<i>ALK</i> is a critical regulator of the <i>MYC</i> -signaling axis in <i>ALK</i> positive lung cancer. <i>Oncotarget</i> , 2018, 9, 8823-8835.	1.8	24
54	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1818-1831.	1.1	133

#	ARTICLE	IF	CITATIONS
55	The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1717-1726.	1.1	119
56	First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small Cell Lung Cancer With Different Prognostic Significance. <i>Clinical Lung Cancer</i> , 2018, 19, 531-543.	2.6	3
57	Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1474-1482.	1.1	130
58	Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent-Front Mutations. <i>Cancer Discovery</i> , 2018, 8, 1227-1236.	9.4	321
59	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). <i>Cancer Discovery</i> , 2017, 7, 400-409.	9.4	647
60	EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. <i>Cancer Research</i> , 2017, 77, 3551-3563.	0.9	65
61	Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1623-1633.	4.1	66
62	Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 504-535.	4.9	994
63	P2.06-007 A Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2017, 12, S1072-S1073.	1.1	3
64	MA16.03 Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2017, 12, S435-S436.	1.1	1
65	P1.02-057 Clinical Utility of ctDNA for Detecting ALK Fusions and Resistance Events in NSCLC: Analysis of a Laboratory Cohort. <i>Journal of Thoracic Oncology</i> , 2017, 12, S522.	1.1	0
66	Targeting Residual Disease in Oncogene-Driven NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1546.	1.1	0
67	Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy. <i>Annals of Oncology</i> , 2017, 28, 2707-2714.	1.2	70
68	Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. <i>Nature Genetics</i> , 2017, 49, 1693-1704.	21.4	423
69	Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. <i>Oncotarget</i> , 2017, 8, 11114-11126.	1.8	22
70	Reply to J.K. Molitoris et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 810-811.	1.6	0
71	Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. <i>Journal of Clinical Oncology</i> , 2017, 35, 1403-1410.	1.6	277
72	Dramatic Response to Crizotinib in a Patient With Lung Cancer Positive for an HLA-DRB1-MET Gene Fusion. <i>JCO Precision Oncology</i> , 2017, 2017, 1-6.	3.0	103

#	ARTICLE	IF	CITATIONS
73	Acral Lentiginous Melanoma Harboring a <i>ROS1</i> Gene Fusion With Clinical Response to Entrectinib. JCO Precision Oncology, 2017, 1, 1-7.	3.0	309
74	Abstract CT060: STARTRK-2: A global phase 2, open-label, basket study of entrectinib in patients with locally advanced or metastatic solid tumors harboring TRK, ROS1, or ALK gene fusions. Cancer Research, 2017, 77, CT060-CT060.	0.9	13
75	Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance. Clinical Lung Cancer, 2016, 17, 466-469.	2.6	16
76	Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience. Archives of Pathology and Laboratory Medicine, 2016, 140, 1206-1220.	2.5	68
77	PS01.68: Heterogeneous Clinical Syndromes Existing Within Patients with Stage IV KRAS Mutant Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2016, 11, S313.	1.1	0
78	Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status. Lung Cancer, 2016, 96, 27-32.	2.0	20
79	An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1273-1281.	1.1	71
80	A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nature Medicine, 2016, 22, 472-478.	30.7	145
81	Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncology, The, 2016, 17, 1672-1682.	10.7	865
82	Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis. Journal of Thoracic Oncology, 2016, 11, 1293-1304.	1.1	143
83	Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 2814-2819.	1.6	37
84	Abstract CT007: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results. Cancer Research, 2016, 76, CT007-CT007.	0.9	17
85	Abstract LB-118: Identification of TRKA and TRKB kinase domain mutations that induce resistance to a pan-TRK inhibitor. , 2016, , .		2
86	Rearranging Detection of Gene Rearrangements. Journal of Thoracic Oncology, 2015, 10, 1129-1130.	1.1	0
87	TRKing Down an Old Oncogene in a New Era of Targeted Therapy. Cancer Discovery, 2015, 5, 25-34.	9.4	509
88	Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer, 2015, 121, 883-892.	4.1	58
89	Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 372, 1700-1709.	27.0	615
90	Molecularly Targeted Therapies in Non-Small-Cell Lung Cancer Annual Update 2014. Journal of Thoracic Oncology, 2015, 10, S1-S63.	1.1	119

#	ARTICLE	IF	CITATIONS
91	An Oncogenic <i>NTRK</i> Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. <i>Cancer Discovery</i> , 2015, 5, 1049-1057.	9.4	343
92	RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. <i>Nature Medicine</i> , 2015, 21, 1038-1047.	30.7	245
93	Abstract 4529: Pharmacokinetics (PK) of LOXO-101 during the first-in-human Phase I study in patients with advanced solid tumors: Interim update. <i>Cancer Research</i> , 2015, 75, 4529-4529.	0.9	10
94	Activation of RAS family members confers resistance to ROS1 targeting drugs. <i>Oncotarget</i> , 2015, 6, 5182-5194.	1.8	72
95	The Minority Report: Targeting the Rare Oncogenes in NSCLC. <i>Current Treatment Options in Oncology</i> , 2014, 15, 644-657.	3.0	12
96	Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3824-3830.	1.6	244
97	<i>ROS1</i> and <i>ALK</i> Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers. <i>Molecular Cancer Research</i> , 2014, 12, 111-118.	3.4	104
98	A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1532-1539.	1.1	47
99	A Nice Problem to Have: When ALK Inhibitor Therapy Works Better Than Expected. <i>Journal of Thoracic Oncology</i> , 2014, 9, 433-435.	1.1	6
100	Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 892-898.	0.8	182
101	Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor. <i>Seminars in Oncology</i> , 2014, 41, 110-125.	2.2	60
102	EGFR Exon 19 Deletion Mutations and Systemic/Central Nervous System Miliary Metastasis: Clinical Correlations and Response to Therapy. <i>Clinical Lung Cancer</i> , 2014, 15, 387-389.	2.6	7
103	Crizotinib in <i>ROS1</i> -Rearranged Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1963-1971.	27.0	1,656
104	The Democratization of the Oncogene. <i>Cancer Discovery</i> , 2014, 4, 870-872.	9.4	7
105	Abstract IA41: A new TRACK in lung cancer: NTRK1 gene fusions as a therapeutic target.. <i>Clinical Cancer Research</i> , 2014, 20, IA41-IA41.	7.0	0
106	Abstract 5255: EGFR is a conspiring kinase in gene fusion positive lung cancer. , 2014, , .		0
107	Time to shift the burden of proof for oncogene-positive cancer?. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 492-493.	27.6	6
108	Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 307-319.	2.3	18

#	ARTICLE	IF	CITATIONS
109	Re-examination of Maintenance Therapy in Non-Small Cell Lung Cancer with the Advent of New Anti-cancer Agents. <i>Drugs</i> , 2013, 73, 517-532.	10.9	5
110	Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. <i>Cancer</i> , 2013, 119, 1467-1477.	4.1	68
111	Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. <i>Nature Medicine</i> , 2013, 19, 1469-1472.	30.7	526
112	Molecular Pathways: ROS1 Fusion Proteins in Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4040-4045.	7.0	310
113	Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. <i>Cancer</i> , 2013, 119, 2383-2390.	4.1	45
114	Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer. <i>Cancer</i> , 2013, 119, 3968-3975.	4.1	47
115	The Evolution of Tumor Classification: A Role for Genomics?. <i>Cancer Cell</i> , 2013, 24, 693-694.	16.8	8
116	Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 636-643.	2.6	25
117	Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2013, 3, 430-443.	9.4	203
118	Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR. <i>Journal of Thoracic Oncology</i> , 2013, 8, e83-e84.	1.1	6
119	Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e82236.	2.5	116
120	Acquired Resistance to Targeted Therapies in Advanced Non-Small Cell Lung Cancer: New Strategies and New Agents. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e272-e278.	3.8	12
121	Abstract 3878: Bach1 promotes liver metastasis of colorectal cancer cells by regulating c-Myc and SOX4.., 2013, , .		1
122	Acquired Resistance to Targeted Therapies in Advanced Non-Small Cell Lung Cancer: New Strategies and New Agents. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e272-e278.	3.8	12
123	Mechanisms of Resistance to Crizotinib in Patients with <i>ALK</i> Gene Rearranged Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1472-1482.	7.0	1,018
124	A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2012, 23, 2094-2102.	1.2	68
125	Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non-small Cell Lung Cancer. <i>Current Cancer Drug Targets</i> , 2012, 12, 107-123.	1.6	47
126	Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1807-1814.	1.1	585

#	ARTICLE	IF	CITATIONS
127	Oncogenic Fusions Involving Exon 19 of ALK. <i>Journal of Thoracic Oncology</i> , 2012, 7, e44.	1.1	6
128	A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 419-426.	1.1	48
129	Targeting ALK, ROS1, and BRAF Kinases. <i>Journal of Thoracic Oncology</i> , 2012, 7, S375-S376.	1.1	10
130	Identifying and Targeting <i>ROS1</i> Gene Fusions in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 4570-4579.	7.0	405
131	Treating ALK-positive lung cancer—early successes and future challenges. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 268-277.	27.6	224
132	Final Results of a Phase 2, Open-Label Study of Ramucirumab (IMC-1121B; RAM), an IGG1 MAB Targeting Vegfr-2, with Paclitaxel and Carboplatin as First-Line Therapy in Patients (PTS) with Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) (NCT00735696). <i>Annals of Oncology</i> , 2012, 23, ix422-ix423.	1.2	0
133	Oncogene status predicts patterns of metastatic spread in treatment-naïve nonsmall cell lung cancer. <i>Cancer</i> , 2012, 118, 4502-4511.	4.1	247
134	Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. <i>Cancer</i> , 2012, 118, 4486-4494.	4.1	88
135	Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. <i>Cancer</i> , 2012, 118, 5302-5309.	4.1	84
136	Abstract LB-449: KRAS mutation and amplification status predicts sensitivity to antifolate therapies in non-small-cell lung cancer. , 2012, , .		2
137	Crizotinib for the treatment of patients with advanced non-small cell lung cancer. <i>Drugs of Today</i> , 2012, 48, 271.	1.1	10
138	A Novel Interplay between Rap1 and PKA Regulates Induction of Angiogenesis in Prostate Cancer. <i>PLoS ONE</i> , 2012, 7, e49893.	2.5	20
139	Abstract 5594: ALK-driven lung cancer: Potential therapeutic strategies for treatment and prevention of drug resistance. , 2012, , .		0
140	Abstract 894: Targeting ROS1 receptor tyrosine kinase gene fusions in non-small cell lung cancer. , 2012, , .		0
141	A time to test, a time to treat. <i>Journal of Thoracic Disease</i> , 2012, 4, 223-5.	1.4	3
142	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. <i>Lancet Oncology</i> , The, 2011, 12, 1004-1012.	10.7	847
143	Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed. <i>Journal of Thoracic Oncology</i> , 2011, 6, 774-780.	1.1	221
144	Reply to M.C. Garassino et al. <i>Journal of Clinical Oncology</i> , 2011, 29, 3837-3838.	1.6	5

#	ARTICLE	IF	CITATIONS
145	Genetic Testing for Lung Cancer: Reflex Versus Clinical Selection. <i>Journal of Clinical Oncology</i> , 2011, 29, 1943-1945.	1.6	14
146	Pharmacodynamic Studies in Early Phase Drug Development. , 2011, , 215-256.		2
147	Abstract 3467: A novel interplay between Rap1, Epac and PKA regulates induction of angiogenesis. , 2011, , .		0
148	Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression. <i>PLoS ONE</i> , 2010, 5, e14117.	2.5	130
149	Biomarkers Are Here to Stay for Clinical Research and Standard Care. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1113-1115.	1.1	6
150	Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (<i>ALK</i>) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment. <i>Clinical Cancer Research</i> , 2010, 16, 5581-5590.	7.0	325
151	New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 69, 1-12.	2.0	59
152	ALK gene rearrangements in unselected caucasians with non-small cell lung carcinoma (NSCLC).. <i>Journal of Clinical Oncology</i> , 2010, 28, 10533-10533.	1.6	15
153	Phase I open-label study of cediranib plus etoposide (E) and cisplatin (P) as first-line therapy for patients (pts) with small cell lung cancer (SCLC) or lung neuroendocrine cancer (NEC).. <i>Journal of Clinical Oncology</i> , 2010, 28, 7050-7050.	1.6	7
154	Abstract 812: Lack of intra-tumoral heterogeneity in lung adenocarcinoma supports gene fusions involving ALK as early clonal events. , 2010, , .		0
155	A novel interplay between Epac/Rap1 and mitogen-activated protein kinase kinase 5/extracellular signal-regulated kinase 5 (MEK5/ERK5) regulates thrombospondin to control angiogenesis. <i>Blood</i> , 2009, 114, 4592-4600.	1.4	43
156	Anthrax Edema Toxin Inhibits Endothelial Cell Chemotaxis via Epac and Rap1. <i>Journal of Biological Chemistry</i> , 2007, 282, 19781-19787.	3.4	59
157	Interaction of HLA-DR with an Acidic Face of HLA-DM Disrupts Sequence-Dependent Interactions with Peptides. <i>Immunity</i> , 2003, 19, 183-192.	14.3	93
158	Point Mutations in or Near the Antigen-Binding Groove of HLA-DR3 Implicate Class II-Associated Invariant Chain Peptide Affinity as a Constraint on MHC Class II Polymorphism. <i>Journal of Immunology</i> , 2003, 170, 4683-4692.	0.8	28
159	Accessory molecules for MHC class II peptide loading. <i>Current Opinion in Immunology</i> , 2000, 12, 99-106.	5.5	90
160	Determination of the HLA-DM Interaction Site on HLA-DR Molecules. <i>Immunity</i> , 2000, 13, 517-527.	14.3	110
161	Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function. <i>Journal of Immunology</i> , 1998, 160, 734-43.	0.8	23
162	Novel glycosylation of HLA-DRalpha disrupts antigen presentation without altering endosomal localization. <i>Journal of Immunology</i> , 1998, 160, 4289-97.	0.8	31

#	ARTICLE	IF	CITATIONS
163	PrlA and PrIG suppressors reduce the requirement for signal sequence recognition. Journal of Bacteriology, 1994, 176, 5607-5614.	2.2	80
164	Novel Fc gamma receptor I family gene products in human mononuclear cells.. Journal of Clinical Investigation, 1992, 90, 2102-2109.	8.2	38